Import from '@/components/mdx'

Can I Take Alpha-Lipoic Acid with AOD-9604?

What AOD-9604 Actually Is, and Why Women Are Using It

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically amino acids 176 to 191 of the hGH C-terminus. Researchers isolated this fragment because it appears to carry hGH's fat-mobilizing activity without the full anabolic and insulin-desensitizing effects of the whole molecule.

How AOD-9604 Works in the Body

In animal studies, AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, promoting lipolysis and inhibiting lipogenesis. A placebo-controlled trial published in the American Journal of Clinical Nutrition found that 1 mg oral AOD-9604 daily produced modest but statistically significant reductions in body weight in obese adults over 24 weeks. The peptide did not raise IGF-1 or affect fasting glucose in that trial's healthy adult cohort, which is a frequently cited reassurance, though the study enrolled predominantly men.

Why the Women's Picture Is Different

Sex-based differences in adipose distribution, beta-adrenergic receptor density, and the way estrogen modulates lipolysis mean that female adipose tissue responds differently to adrenergic signaling than male adipose tissue. Estrogen upregulates alpha-2 adrenergic receptors in gluteofemoral fat, which blunts lipolytic response. This is one reason body fat distribution and fat-loss response to adrenergic compounds differ between pre-menopausal and post-menopausal women. No published trial has reported AOD-9604 outcomes stratified by sex or hormonal status. That gap matters, and you deserve to know it exists.

AOD-9604 is currently available only through 503A compounding pharmacies in the United States and is not approved by the FDA for any indication. Prescribing is off-label.

What Alpha-Lipoic Acid Does, and Why Women Take It

Alpha-lipoic acid is a mitochondrial co-enzyme with antioxidant properties. It is both water- and fat-soluble, which makes it unusual among antioxidants. Women take it for insulin resistance, PCOS-related metabolic symptoms, neuropathy, weight management, and anti-aging protocols.

ALA's Blood Sugar Effects

ALA activates the enzyme AMP-activated protein kinase (AMPK) and improves glucose uptake in skeletal muscle by enhancing GLUT4 translocation. A meta-analysis of 23 randomized controlled trials found that ALA supplementation significantly reduced fasting blood glucose (weighted mean difference: minus 1.35 mmol/L) and insulin resistance (HOMA-IR reduction: minus 1.49) compared with placebo. These are meaningful numbers in clinical practice.

ALA in PCOS

In women with PCOS, a randomized trial of 400 mg ALA daily for 16 weeks showed significant improvements in insulin sensitivity and reductions in testosterone compared with placebo. Because PCOS is the most common endocrine disorder in reproductive-age women, affecting 6 to 13 percent of women globally, ALA use in this population is common, and the interaction question with AOD-9604 is directly relevant.

ALA and Thyroid Hormone Conversion

Animal studies have shown that high-dose ALA inhibits deiodinase enzymes, specifically type 1 iodothyronine deiodinase, which converts inactive T4 to active T3. A study in rats demonstrated reduced serum T3 and elevated reverse T3 at doses equivalent to approximately 600 mg/day in humans. Human data remain sparse, but case reports exist of women on ALA noting worsened hypothyroid symptoms or shifts in their free T3/T4 ratio. This is not proven in controlled human trials, and it may be a dose-dependent effect.

The Interaction: Pharmacokinetic or Pharmacodynamic?

This combination's risks fall into two categories, and knowing which type matters because the management strategy differs.

Pharmacodynamic Interaction: Additive Hypoglycemia

A pharmacodynamic interaction means two agents affect the same physiologic pathway independently. Both ALA and AOD-9604 can influence glucose and insulin dynamics, though through different routes. ALA does so directly via AMPK activation and improved insulin receptor signaling. AOD-9604 does so indirectly: by increasing lipolysis, it raises circulating free fatty acids acutely, which in theory competes with glucose oxidation (the Randle cycle), but the peptide's overall metabolic footprint appears to favor improved fat metabolism rather than frank hypoglycemia in isolation.

The concern is not that either agent alone is reliably hypoglycemic at typical doses, but that women who are also managing insulin resistance, are calorie-restricting, or are on medications like metformin or insulin face a compounded risk of blood sugar dropping lower than intended. A 2012 review of ALA's glucose-lowering mechanisms noted that doses above 600 mg/day carry a meaningful risk of symptomatic hypoglycemia when combined with other insulin-sensitizing agents.

Pharmacokinetic Interaction: Thyroid Hormone Metabolism

A pharmacokinetic interaction affects how a drug is absorbed, distributed, metabolized, or eliminated. ALA's inhibitory effect on deiodinase enzymes is a metabolic (pharmacokinetic) interference with thyroid hormone activation. AOD-9604 itself does not appear to affect thyroid function directly based on available animal and limited human data. However, growth hormone fragments can influence the hypothalamic-pituitary axis in ways that affect thyroid-stimulating hormone (TSH) release. The clinical significance of combining these two effects has not been studied. Women who already carry a subclinical hypothyroid pattern, which is far more prevalent in women than men (affecting approximately 5 percent of women in the U.S. Versus 1 to 2 percent of men), are the subgroup most exposed to this combined risk.

Why Your Hormonal Life Stage Changes This Risk Profile

Different hormonal life stages change how both compounds behave in your body. Here is a stage-by-stage breakdown, because "women" is not a monolithic category.

Reproductive Years (Pre-Menopausal, Not Trying to Conceive)

Your estrogen status modulates AMPK activity independently. Estrogen itself activates AMPK in several tissues, which means ALA's AMPK-based effects may be additive with endogenous estrogen signaling during the follicular phase. Blood sugar fluctuations across your menstrual cycle are real: insulin sensitivity is higher in the follicular phase and lower in the luteal phase due to progesterone's insulin-antagonizing effect. If you are adding ALA and AOD-9604 to this already-shifting baseline, you may notice more pronounced glucose dipping in the follicular phase. Tracking continuous glucose monitor data across your cycle is reasonable if you are on this combination.

Trying to Conceive

Do not use AOD-9604 while actively trying to conceive. No human safety data exist for the peptide in conception cycles. ALA at doses up to 600 mg/day has not shown harm in conception-related trials, but the combination is unstudied.

Perimenopause

This is the life stage where the interaction risks cluster most densely. Estrogen withdrawal in perimenopause increases central adiposity, worsens insulin resistance, and raises the prevalence of subclinical hypothyroidism. Women in perimenopause are frequently prescribed or seek out both ALA (for metabolic support) and peptides like AOD-9604 (for fat distribution changes). Thyroid function is already under pressure in this group. Getting a full thyroid panel, including free T3, before starting this combination is not optional, it is the responsible approach.

Post-Menopause

Post-menopausal women have lower baseline metabolic rates and are more likely to be on thyroid replacement therapy, statins, or antidiabetic medications, all of which expand the interaction surface. If you take levothyroxine, ALA at doses above 300 mg/day should be separated by at least four hours from your thyroid medication to avoid absorption interference. AOD-9604 layered on top adds an unquantified variable.

Pregnancy and Lactation Safety

AOD-9604 is contraindicated in pregnancy. There are no human trials of AOD-9604 in pregnant women. Animal reproductive toxicity studies are not published in the peer-reviewed literature for this specific fragment. The FDA has not assigned a pregnancy category to AOD-9604 because it is not an approved drug. Compounding pharmacies are not required to conduct reproductive safety testing. Given that hGH receptor signaling plays a role in placental development and fetal growth, using an hGH fragment during pregnancy is not acceptable outside of a formal clinical trial.

AOD-9604 should be stopped at least one full menstrual cycle before a planned conception attempt, and reliable contraception is required during use in reproductive-age women unless pregnancy has been definitively excluded.

For lactation, no data exist on AOD-9604 transfer into breast milk. The default position for any peptide without lactation safety data is to avoid it during breastfeeding.

Alpha-lipoic acid has a somewhat better-characterized pregnancy profile. A Cochrane-adjacent systematic review found ALA used in the context of diabetic neuropathy during pregnancy had no significant adverse fetal outcomes reported, though controlled data are scarce. ALA transfers into breast milk in animal models. Human lactation data are insufficient to establish safety. Conservative practice is to pause ALA above 200 mg/day during breastfeeding unless benefit clearly outweighs the unknown risk.

Monitoring: What to Check Before and During Use

If you are already taking both or considering the combination, these are the specific labs and symptoms that matter.

Baseline Labs Before Starting the Combination

• Fasting glucose and insulin, with HOMA-IR calculation
• HbA1c if you have metabolic risk factors or PCOS
• Full thyroid panel: TSH, free T4, free T3, reverse T3
• Complete metabolic panel (liver function, as ALA is hepatically metabolized)

Monitoring During Use

• Recheck fasting glucose and insulin at 6 to 8 weeks
• Recheck thyroid panel at 12 weeks, sooner if you notice fatigue, cold intolerance, hair loss, or weight gain despite the protocol
• Watch for hypoglycemia symptoms: shakiness, sweating, confusion, or heart pounding, especially in the two to three hours after your ALA dose
• If you wear a continuous glucose monitor, note whether your overnight readings trend lower after starting ALA

Dose-Separation Strategy

Because ALA is absorbed rapidly (peak plasma concentration at 30 to 60 minutes after ingestion), and AOD-9604 is typically administered subcutaneously in the morning or evening, separating the two by at least 90 minutes reduces the overlap of their peak activity windows. This is pragmatic, not evidence-based from a direct interaction study, because that study does not exist.

Who This Combination May Be Right For, and Who Should Avoid It

Potentially Appropriate Candidates

• Women in perimenopause or post-menopause with documented insulin resistance who are not on antidiabetic medications and who have normal thyroid function at baseline
• Women with PCOS who are not pregnant or trying to conceive, have had baseline labs, and are working with a clinician who can monitor them
• Women using AOD-9604 as part of a supervised compounding pharmacy protocol who want metabolic support from ALA and have no thyroid pathology

Who Should Avoid This Combination or Use Extreme Caution

• Women who are pregnant, breastfeeding, or actively trying to conceive (avoid AOD-9604 entirely in this group)
• Women with known hypothyroidism or who are on levothyroxine, especially without specialist oversight
• Women already taking metformin, insulin, GLP-1 receptor agonists (such as semaglutide or tirzepatide), or other insulin-sensitizing agents, because the additive hypoglycemia risk becomes clinically meaningful
• Women with a history of hypoglycemia unawareness
• Women with active liver disease, since both compounds are hepatically metabolized

The Evidence Gap: What We Do Not Know

Honesty about missing data is part of responsible clinical writing. Here is what the literature does not yet tell us.

No published trial has examined AOD-9604 and ALA together in any population, male or female. The interaction concern is constructed from the individual pharmacology of each compound, which is the standard approach when direct combination data are absent, but it means the risk magnitude is estimated, not measured.

No trial of AOD-9604 has been designed with a female-only or female-stratified cohort. The foundational Heffernan et al. 2001 trial in the American Journal of Clinical Nutrition did not report sex-stratified outcomes. Women should know they are extrapolating from data gathered largely in men and mixed populations.

The thyroid interaction signal for ALA comes from rodent pharmacology, not from controlled human trials. It is a plausible concern, not a confirmed clinical hazard. The signal is strong enough to warrant monitoring but not so strong that it categorically prohibits use in a euthyroid woman who wants both.

As of January 2025, no FDA-recognized safety database entry for AOD-9604 exists because it is not an approved drug. The Natural Medicines database rates the ALA-blood-sugar interaction as "likely" clinically significant when combined with antidiabetic drugs, and the AOD-9604 entry is classified as "insufficient evidence" for most outcomes, which is the honest state of the literature.

Practical Protocol If You Are Already Taking Both

If you are already on this combination and feeling fine, do not panic. Do schedule a review with your prescribing clinician within the next four weeks and request the baseline labs listed above if you have not had them. Specifically ask for free T3 alongside TSH, because TSH alone can be normal even when T3 conversion is impaired.

If you have been on ALA for more than 90 days at doses above 600 mg/day and are adding AOD-9604, consider stepping your ALA dose down to 300 to 400 mg/day for the first eight weeks of the combination to reduce the additive metabolic load while your body adjusts.

If you notice any of the following after starting the combination, contact your clinician: unexplained fatigue lasting more than two weeks, new or worsening hair thinning, episodes of shakiness or sweating not explained by exercise, or cold intolerance that is new. These symptoms can reflect thyroid disruption, hypoglycemia, or both.

A 2021 systematic review of ALA supplementation safety reported that adverse effects at doses below 600 mg/day were rare and mostly gastrointestinal. Doses above 1,200 mg/day were associated with more frequent nausea and a higher incidence of metabolic side effects. Staying at or below 600 mg/day while on AOD-9604 is the conservative and defensible position until better combination data exist.